Key facts
- This page summarizes Michael S. Lee's Form 4 filing for FATE THERAPEUTICS INC (FATE).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 15 Jun 2026, 17:15.
Michael S. Lee - 12 Jun 2026 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)
- Reporting relationship
- Director
- Issuer ticker
- FATE
- Reported as of
- 12 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Jun 2026, 17:15:44 UTC
- Prior SEC filing
- 14 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael S. Lee
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael S. Lee filed Form 4 for FATE THERAPEUTICS INC (FATE) on 15 Jun 2026.
Change
- Previous filing in this sequence was filed on 14 Aug 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001748010
Primary reporting owner
Lee Michael Stewart
- Relationship
- Director
- Address
- C/O REDMILE GROUP, LLC, 900 LARKSPUR LANDING CIRCLE, SUITE 270, LARKSPUR
- Signature
- /s/ Michael S. Lee
- Signature date
- 15 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FATE
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +87,900
- Change %
- Price
- $0.000000*
- Shares after
- 87,900
- Date
- 12 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 87,900
- Exercise price
- $2.06
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The stock option will vest in full and become exercisable upon the earlier of (i) June 12, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to Michael Lee's continued service on the board of directors of the Issuer through the applicable vesting date.
Footnote F2
The stock option award was granted to Mr. Lee in connection with his service as a member of the board of directors of the Issuer. Mr. Lee, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Lee holds this stock option award as a nominee on behalf, and for the sole benefit, of Redmile and has assigned all economic, pecuniary and voting rights in respect of the stock option award to Redmile. Mr. Lee disclaims beneficial ownership of the stock option award, if any, and the filing of this Form 4 shall not be deemed an admission that Mr. Lee is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Footnote F3
The stock option award may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green disclaim beneficial ownership of the stock option award except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Footnote F4
Mr. Lee was elected to the board of directors of the Issuer as a representative of Redmile and its affiliates. As a result, Redmile and Mr. Green are directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended.